Login to Your Account



Too Targeted?

Selective PI3K Deals Abound, But is Targeted Always Best?

By Trista Morrison
Editor

Monday, February 27, 2012

While early efforts to target phosphoinositide-3 kinase (PI3K) involved pan-inhibition, biotechs like Intellikine Inc. and Calistoga Pharmaceuticals Inc. differentiated themselves by selectively targeting the alpha, beta, delta and/or gamma isoforms of PI3K rather than hitting the whole family.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription